UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa
Retrieved on:
Thursday, March 16, 2023
Abstract, Psoriatic arthritis, Bimekizumab, Secukinumab, Psoriasis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Skin, BE, Maintenance, AAD, UCB, American Academy, Patient, Conditional sentence, Psoriasis Area and Severity Index, Welsh Terrier, HS, Hidradenitis suppurativa, Week, Safety, Food, American Academy of Dermatology, Phase 3, Pharmaceutical industry, Medical imaging
The abstracts have been accepted as one late-breaking oral platform presentation and seven posters, including three with oral presentations.
Key Points:
- The abstracts have been accepted as one late-breaking oral platform presentation and seven posters, including three with oral presentations.
- Five of the eight abstracts at AAD 2023 will share data on bimekizumab in the treatment of moderate to severe plaque psoriasis, including data evaluating bimekizumab in the treatment of nail psoriasis from the BE RADIANT Phase 3b trial.
- Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial.
- Bimekizumab improved efficacy measures in patients with active psoriatic arthritis and moderate or severe psoriasis: Pooled 16-week results from phase 3 randomized, placebo-controlled studies BE OPTIMAL and BE COMPLETE.